Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on Immunization session in Viet Nam: results of a comparative randomized trial
- 30 April 1999
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 93 (2), 208-213
- https://doi.org/10.1016/s0035-9203(99)90309-7
Abstract
The World Health Organization recently recommended a rabies vaccine pre-exposure schedule using 3 intradermal (i.d.) injections of one-fifth the standard intramuscular (i.m.) dose of current cell culture vaccines as a cost-reducing alternative for developing countries. As a strategy to improve further the acceptability of childhood rabies immunization, we assessed, in a controlled, randomized trial performed in 240 Vietnamese infants, the possibility of associating i.d. administration of a one-fifth dose of purified Vero-cell rabies vaccine (PVRV) with routine Expanded Programme on Immunization vaccines given at 2, 3 and 4 months of age (diphtheria, tetanus, whole-cell pertussis and inactivated poliomyelitis combined vaccine, DTP-IPV). Safety and immunogenicity results were compared with a group of infants given 2 i.m. doses of PVRV (2, 4 months) in association with DTP-IPV (2, 3, 4 months). After i.d. injection, more infants experienced local reactions, particularly redness, but these reactions were generally mild and transient. The rate of systemic reactions was the same in both groups. Although the rabies antibody titres (rapid fluorescent focus inhibition test) were higher 1 month after the third vaccine dose in the i.m. group (30.6 IU/mL vs 12.0 IU/mL in the i.d. group), all infants in both groups had achieved WHO-acceptable protective antibody titres (> or = 0.5 IU/mL) at this time. There was no evidence for any interference between DTP-IPV and rabies vaccine, supporting the interest of a low-dose i.d. PVRV pre-exposure regimen in infants living in rabies-endemic developing countries.Keywords
This publication has 19 references indexed in Scilit:
- Influence of disease burden, public perception, and other factors on new vaccine development, implementation, and continued useThe Lancet, 1997
- Prospects for the use of new vaccines in developing countries: cost is not the only impedimentVaccine, 1996
- Rabies vaccine standardization: International collaborative study for the characterization of the fifth international standard for rabies vaccineBiologicals, 1992
- RabiesThe Lancet, 1990
- Human diploid cell rabies vaccine purified by zonal centrifugation: a controlled study of antibody response and side effects following primary and booster pre-exposure immunizationsVaccine, 1989
- Acceptability and Efficacy of Purified Vero-Cell Rabies Vaccine in Thai Children Exposed to RabiesAsia-Pacific journal of public health, 1988
- A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailabilityJournal of Pharmacokinetics and Biopharmaceutics, 1987
- Rabies Preexposure Prophylaxis with Human Diploid Cell Rabies Vaccine: A Dose-Response StudyThe Journal of Infectious Diseases, 1987
- RABIES VACCINE FOR HUMAN USE, CULTIVATED ON VERO CELLSThe Lancet, 1986
- MULTI-SITE INTRADERMAL AND MULTI-SITE SUBCUTANEOUS RABIES VACCINATION: IMPROVED ECONOMICAL REGIMENSThe Lancet, 1984